Cargando…
Immune Evasion, Infectivity, and Fusogenicity of SARS-CoV-2 Omicron BA.2.86 and FLip Variants
Evolution of SARS-CoV-2 requires the reassessment of current vaccine measures. Here, we characterized BA.2.86 and the XBB-lineage variant FLip by investigating their neutralization alongside D614G, BA.1, BA.2, BA.4/5, XBB.1.5, and EG.5.1 by sera from 3-dose vaccinated and bivalent vaccinated healthc...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cold Spring Harbor Laboratory
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10515800/ https://www.ncbi.nlm.nih.gov/pubmed/37745517 http://dx.doi.org/10.1101/2023.09.11.557206 |
_version_ | 1785109021795024896 |
---|---|
author | Qu, Panke Xu, Kai Faraone, Julia N. Goodarzi, Negin Zheng, Yi-Min Carlin, Claire Bednash, Joseph S. Horowitz, Jeffrey C. Mallampalli, Rama K. Saif, Linda J. Oltz, Eugene M. Jones, Daniel Gumina, Richard J. Liu, Shan-Lu |
author_facet | Qu, Panke Xu, Kai Faraone, Julia N. Goodarzi, Negin Zheng, Yi-Min Carlin, Claire Bednash, Joseph S. Horowitz, Jeffrey C. Mallampalli, Rama K. Saif, Linda J. Oltz, Eugene M. Jones, Daniel Gumina, Richard J. Liu, Shan-Lu |
author_sort | Qu, Panke |
collection | PubMed |
description | Evolution of SARS-CoV-2 requires the reassessment of current vaccine measures. Here, we characterized BA.2.86 and the XBB-lineage variant FLip by investigating their neutralization alongside D614G, BA.1, BA.2, BA.4/5, XBB.1.5, and EG.5.1 by sera from 3-dose vaccinated and bivalent vaccinated healthcare workers, XBB.1.5-wave infected first responders, and monoclonal antibody (mAb) S309. We assessed the biology of the variant Spikes by measuring viral infectivity and membrane fusogenicity. BA.2.86 is less immune evasive compared to FLip and other XBB variants, consistent with antigenic distances. Importantly, distinct from XBB variants, mAb S309 was unable to neutralize BA.2.86, likely due to a D339H mutation based on modeling. BA.2.86 had relatively high fusogenicity and infectivity in CaLu-3 cells but low fusion and infectivity in 293T-ACE2 cells compared to some XBB variants, suggesting a potentially differences conformational stability of BA.2.86 Spike. Overall, our study underscores the importance of SARS-CoV-2 variant surveillance and the need for updated COVID-19 vaccines. |
format | Online Article Text |
id | pubmed-10515800 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Cold Spring Harbor Laboratory |
record_format | MEDLINE/PubMed |
spelling | pubmed-105158002023-09-23 Immune Evasion, Infectivity, and Fusogenicity of SARS-CoV-2 Omicron BA.2.86 and FLip Variants Qu, Panke Xu, Kai Faraone, Julia N. Goodarzi, Negin Zheng, Yi-Min Carlin, Claire Bednash, Joseph S. Horowitz, Jeffrey C. Mallampalli, Rama K. Saif, Linda J. Oltz, Eugene M. Jones, Daniel Gumina, Richard J. Liu, Shan-Lu bioRxiv Article Evolution of SARS-CoV-2 requires the reassessment of current vaccine measures. Here, we characterized BA.2.86 and the XBB-lineage variant FLip by investigating their neutralization alongside D614G, BA.1, BA.2, BA.4/5, XBB.1.5, and EG.5.1 by sera from 3-dose vaccinated and bivalent vaccinated healthcare workers, XBB.1.5-wave infected first responders, and monoclonal antibody (mAb) S309. We assessed the biology of the variant Spikes by measuring viral infectivity and membrane fusogenicity. BA.2.86 is less immune evasive compared to FLip and other XBB variants, consistent with antigenic distances. Importantly, distinct from XBB variants, mAb S309 was unable to neutralize BA.2.86, likely due to a D339H mutation based on modeling. BA.2.86 had relatively high fusogenicity and infectivity in CaLu-3 cells but low fusion and infectivity in 293T-ACE2 cells compared to some XBB variants, suggesting a potentially differences conformational stability of BA.2.86 Spike. Overall, our study underscores the importance of SARS-CoV-2 variant surveillance and the need for updated COVID-19 vaccines. Cold Spring Harbor Laboratory 2023-09-12 /pmc/articles/PMC10515800/ /pubmed/37745517 http://dx.doi.org/10.1101/2023.09.11.557206 Text en https://creativecommons.org/licenses/by-nc/4.0/This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (https://creativecommons.org/licenses/by-nc/4.0/) , which allows reusers to distribute, remix, adapt, and build upon the material in any medium or format for noncommercial purposes only, and only so long as attribution is given to the creator. |
spellingShingle | Article Qu, Panke Xu, Kai Faraone, Julia N. Goodarzi, Negin Zheng, Yi-Min Carlin, Claire Bednash, Joseph S. Horowitz, Jeffrey C. Mallampalli, Rama K. Saif, Linda J. Oltz, Eugene M. Jones, Daniel Gumina, Richard J. Liu, Shan-Lu Immune Evasion, Infectivity, and Fusogenicity of SARS-CoV-2 Omicron BA.2.86 and FLip Variants |
title | Immune Evasion, Infectivity, and Fusogenicity of SARS-CoV-2 Omicron BA.2.86 and FLip Variants |
title_full | Immune Evasion, Infectivity, and Fusogenicity of SARS-CoV-2 Omicron BA.2.86 and FLip Variants |
title_fullStr | Immune Evasion, Infectivity, and Fusogenicity of SARS-CoV-2 Omicron BA.2.86 and FLip Variants |
title_full_unstemmed | Immune Evasion, Infectivity, and Fusogenicity of SARS-CoV-2 Omicron BA.2.86 and FLip Variants |
title_short | Immune Evasion, Infectivity, and Fusogenicity of SARS-CoV-2 Omicron BA.2.86 and FLip Variants |
title_sort | immune evasion, infectivity, and fusogenicity of sars-cov-2 omicron ba.2.86 and flip variants |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10515800/ https://www.ncbi.nlm.nih.gov/pubmed/37745517 http://dx.doi.org/10.1101/2023.09.11.557206 |
work_keys_str_mv | AT qupanke immuneevasioninfectivityandfusogenicityofsarscov2omicronba286andflipvariants AT xukai immuneevasioninfectivityandfusogenicityofsarscov2omicronba286andflipvariants AT faraonejulian immuneevasioninfectivityandfusogenicityofsarscov2omicronba286andflipvariants AT goodarzinegin immuneevasioninfectivityandfusogenicityofsarscov2omicronba286andflipvariants AT zhengyimin immuneevasioninfectivityandfusogenicityofsarscov2omicronba286andflipvariants AT carlinclaire immuneevasioninfectivityandfusogenicityofsarscov2omicronba286andflipvariants AT bednashjosephs immuneevasioninfectivityandfusogenicityofsarscov2omicronba286andflipvariants AT horowitzjeffreyc immuneevasioninfectivityandfusogenicityofsarscov2omicronba286andflipvariants AT mallampalliramak immuneevasioninfectivityandfusogenicityofsarscov2omicronba286andflipvariants AT saiflindaj immuneevasioninfectivityandfusogenicityofsarscov2omicronba286andflipvariants AT oltzeugenem immuneevasioninfectivityandfusogenicityofsarscov2omicronba286andflipvariants AT jonesdaniel immuneevasioninfectivityandfusogenicityofsarscov2omicronba286andflipvariants AT guminarichardj immuneevasioninfectivityandfusogenicityofsarscov2omicronba286andflipvariants AT liushanlu immuneevasioninfectivityandfusogenicityofsarscov2omicronba286andflipvariants |